Valuation: AnaptysBio, Inc.

Capitalization 1.84B 1.58B 1.45B 1.38B 2.53B 176B 2.57B 17.35B 6.71B 83.7B 6.9B 6.75B 292B P/E ratio 2026 *
151x
P/E ratio 2027 * 14.8x
Enterprise value 1.93B 1.66B 1.52B 1.45B 2.66B 185B 2.7B 18.21B 7.05B 87.87B 7.24B 7.09B 306B EV / Sales 2026 *
17.2x
EV / Sales 2027 * 9.96x
Free-Float
94.26%
Yield 2026 *
-
Yield 2027 * -
1 day+1.54%
1 week-8.91%
Current month-3.93%
1 month-6.46%
3 months+17.61%
6 months+81.62%
Current year+30.26%
1 week 57.85
Extreme 57.85
68.34
1 month 44
Extreme 44
72.36
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 20/03/2022
Director of Finance/CFO 42 10/05/2026
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 79 29/06/2015
Director/Board Member 63 29/06/2015
Director/Board Member 49 07/04/2021
Change 5d. change 1-year change 3-years change Capi.($)
+1.54%-8.91%+212.31%+231.50% 1.84B
-1.88%-1.59%+34.16%+76.26% 50.1B
+0.12%-3.44%+68.07%+52.11% 45.82B
-5.60%+7.69%+60.22%+488.04% 23.66B
-2.65%-4.86%-3.47%-14.84% 22.65B
-2.20%-0.36%+38.69%-24.45% 17.8B
+0.28%+1.72%+27.84%-42.05% 16.08B
-5.32%-13.33%+36.21%+207.57% 14.14B
-7.00%-6.69%-29.33%+898.22% 13.09B
-2.84%-5.57%+28.16% - 13B
Average -2.56%-2.90%+47.29%+208.04% 21.82B
Weighted average by Cap. -2.37%-1.37%+37.57%+153.18%

Financials

2026 *2027 *
Net sales 112M 96.38M 88.12M 84.08M 154M 10.75B 157M 1.06B 409M 5.1B 420M 411M 17.77B 154M 133M 121M 116M 212M 14.81B 216M 1.46B 564M 7.03B 579M 567M 24.49B
Net income 13.02M 11.2M 10.24M 9.77M 17.91M 1.25B 18.21M 123M 47.55M 593M 48.85M 47.8M 2.07B 141M 121M 111M 106M 194M 13.51B 197M 1.33B 514M 6.41B 528M 517M 22.34B
Net Debt 91.63M 78.84M 72.09M 68.78M 126M 8.79B 128M 865M 335M 4.17B 344M 336M 14.54B -300M -258M -236M -225M -413M -28.81B -420M -2.83B -1.1B -13.68B -1.13B -1.1B -47.65B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
15/05/26 63.15 $ +1.54% 448,355
14/05/26 62.19 $ -0.79% 469,529
13/05/26 62.68 $ -4.41% 844,570
12/05/26 65.58 $ -3.45% 854,058
11/05/26 67.92 $ -2.03% 504,139
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
63.15USD
Average target price
84.36USD
Spread / Average Target
+33.59%

Quarterly revenue - Rate of surprise